1 / 17

The Importance of Beta-Blockers in Patients with Heart Failure:

The Importance of Beta-Blockers in Patients with Heart Failure: A R esynchronization-Defibrillation for A mbulatory Heart F ailure T rial ( RAFT ) Analysis . L. Brent Mitchell, Jean L. Rouleau , Gary E. Newton, Jonathon Howlett , Elizabeth Yetisir , George A. Wells, Anthony S.L. Tang.

emma
Télécharger la présentation

The Importance of Beta-Blockers in Patients with Heart Failure:

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The Importance of Beta-Blockers in Patients with Heart Failure: A Resynchronization-Defibrillation for Ambulatory Heart Failure Trial (RAFT) Analysis. L. Brent Mitchell, Jean L. Rouleau, Gary E. Newton, Jonathon Howlett, Elizabeth Yetisir, George A. Wells, Anthony S.L. Tang

  2. DECLARATION - 1 Declaration of Potential Conflict of Interest CRT • I have nothing to declare Aldo Block ACE-I / ARB Beta-Blockers

  3. BACKGROUND - 1 CHF - Proven Effective Therapies on All-Cause Mortality CRT ICD Aldo Block ACE-I / ARB Beta-Blockers

  4. BACKGROUND - 2 Resynchronization-defibrillation for Ambulatory heart Failure Trial (RAFT) • multicenter, randomized, two parallel-group, clinical trial • 1798 patients with NYHA II/III congestive heart failure • receiving optimal medical therapy • with LVEF ≤ 0.30 and QRSd ≥ 120ms (≥ 200ms if V-paced) • and with an independent indication for an ICD • were randomized 1:1 to receive an ICD or a CRT-ICD

  5. BACKGROUND - 3 RAFT Results: Death or CHF Hospitalization ICD HR = 0.75 95% CI: 0.64 – 0.87 p < 0.001 60 50 40 CRT-ICD Cumulative Incidence 30 20 10 0 5 0 1 2 3 4 6 Years of Follow-up Tang AS et al. N Engl J Med 363:2385-95, 2010

  6. BACKGROUND - 4 CHF - Proven Effective Therapies on All-Cause Mortality CRT ICD Aldo Block ACE-I / ARB Beta-Blockers

  7. PURPOSE To assess the contemporary importance, independence, and dose-dependence of beta-blocker therapy in the congestive heart failure patients studied in RAFT.

  8. METHODS PATIENT POPULATION: RAFT patients that were treated with one of bisoprolol, carvedilol, or metoprolol. BETA-BLOCKER TARGET DOSAGES: were as defined by ESC guidelines1 - bisoprolol 10 mg/d, carvedilol 50 mg/d, metoprolol 200 mg/d. PRIMARY OUTCOME: death or CHF hospitalization. STATISTICS: Times to outcome displayed as KM curves. Sixteen variables were included in stepwise proportional hazards analyses. 1. McMurray JJV et al. Eur Heart J 33:1787-847, 2012

  9. RESULTS - 1 The RAFT Patient Population: • N = 1798, mean age 66 yrs, 83% male, 67% ischemic • 80% NYHA Class II, mean LVEF 0.23 • 90% beta-blocker use, 97% ACE-I / ARB use • 42% spironolactone use This Substudy Patient Population (82%): • N = 1474, mean age 66 yrs, 83% male, 66% ischemic • 82% NYHA Class II, mean LVEF 0.23 • 100% beta-blocker use, 97% ACE-I / ARB use • 42% spironolactone use

  10. RESULTS - 2 Beta-Blocker Use Distributions 629 < 50% target ≥ 50% target p < 0.001 489 number 356 (34%) (39%) (67%)

  11. RESULTS - 3 Population Differences by Beta-Blocker Dosage

  12. RESULTS - 4 Death / CHF Hospitalization by Beta-Blocker Dosage HR = 1.50 95% CI = 1.24 – 1.81 p < 0.001 60 < 50% 50 40 Cumulative Incidence 30 ≥ 50% 20 10 0 5 0 1 2 3 4 6 Years of Follow-up

  13. RESULTS - 5 Independent Predictors of Primary Outcome

  14. RESULTS - 6 Death / CHF Hospitalization by Beta-Blocker Dosage by bisoprolol dosage (N=489) by beta-blocker dosage (N=1474) p < 0.0001 p < 0.0001 60 60 60 60 < 50% < 50% 40 Incidence 20 ≥ 50% ≥ 50% 40 40 40 0 5 0 1 2 3 4 6 by carvedilol dosage (N=629) by metoprolol dosage (N=356) p < 0.0001 p = 0.006 20 20 20 < 50% < 50% Incidence ≥ 50% ≥ 50% 0 0 0 5 5 5 0 0 0 1 1 1 2 2 2 3 3 3 4 4 4 6 6 6 Years of Follow-up Years of Follow-up

  15. RESULTS - 7 Death / CHF Hospitalization by RAFT Randomisation Randomised to CRT-ICD (N=740) Randomised to ICD (N=734) p < 0.001 p = 0.07 60 60 < 50% < 50% 40 40 Cumulative Incidence 20 20 ≥ 50% ≥ 50% 0 0 5 5 0 0 1 1 2 2 3 3 4 4 6 6 Years of Follow-up Years of Follow-up

  16. INFERENCES In this subgroup analysis of CHF patients studied in RAFT: • independent predictors of death / CHF hospitalization were: • beta-blockers use at < 50% (not ≥ 50%) of target dosage • use of an ICD (not a CRT-ICD) • ischemic heart disease and previous CABG • peripheral vascular disease or impaired renal function • with lower dosage these outcome were 50% more likely • there were no efficacy differences among the beta-blockers • carvedilol is more often used at ≥ 50% of target dosages • the superiority of higher beta-blocker dosages are less evident in CRT-ICD patients than in ICD patients

  17. The Importance of Beta-Blockers in Patients with Heart Failure: A Resynchronization-Defibrillation for Ambulatory Heart Failure Trial (RAFT) Analysis. L. Brent Mitchell, Jean L. Rouleau, Gary E. Newton, Jonathon Howlett, Elizabeth Yetisir, George A. Wells, Anthony S.L. Tang

More Related